Treatment of exogenous allergic alveolitis
Last reviewed: 19.10.2021
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Obligatory is the elimination regime (cessation of contact with the allergen). In the acute phase, glucocorticoids are prescribed, for example prednisolone up to 2 mg / kg per day orally. Reduce the dose should be gradually from the beginning of the positive dynamics of the clinical picture (reduction of dyspnea, cough, normalization of FVD). Then a maintenance dose of prednisolone 5 mg per day for 2-3 months is prescribed. Option: pulse therapy with methylprednisolone 10-30 mg / kg (up to 1 g) 1-3 days, once a month for 3-4 months. In the chronic stage of exogenous allergic alveolitis, the maintenance dose of prednisolone is prescribed for 6-8 months, sometimes longer.
It is also necessary to carry out respiratory gymnastics and exercise therapy, as indicated by symptomatic therapy (bronchodilators, mucolytics). In some cases, plasmapheresis, hemosorption and immunosorption are used.
Forecast of exogenous allergic alveolitis
The acute phase of exogenous allergic alveolitis shows a favorable prognosis when contact with allergens is stopped and timely adequate treatment. When the disease progresses to the chronic stage, the prognosis becomes quite serious. Even after cessation of contact with the allergen, the progression of the disease continues and is not amenable to therapy. The situation is aggravated with the development of the pulmonary heart.